1. Efficacy and limitations of 68-gallium DOTATATE PET/CT for neuroendocrine tumors: clinical experience following FDA approval. (March 2018) Authors: Griffith, R.W.; McDonald, E.; Emmonds, L.; Gerhold, J.; Cohn, A.L.; Liu, E. Journal: HPB Issue: Volume 20(2018)Supplement 1 Page Start: S91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗